ArticleFrontiers in pharmacology2026
Taletrectinib in ROS1+ non-small cell lung cancer: a cost-effectiveness analysis in the United States.
Gengwei Huo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it